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ABSTRACT 
JCV is a small, naked tumor polyomavirus with an icosahedral capsids containing a 
circular, double-stranded DNA genome. Its genome is divided into early and late 
genes, separated by a non-coding control region (NCCR) containing the promoter, 
the origin of replication (ORI) and the enhancer elements. Early genes encode for 
large T antigen, small t antigen and three different T’ proteins called T’135, T’136 
and T’165. Late genes encode for the structural proteins VP1, VP2 and VP3, and 
the non-structural agnoprotein. JCV only replicates in human. In non-permissive 
cells, they are not able to support viral replication or expression of late genes. In 
those cells, only the transcription of early genes is observed, such as large T antigen. 
This leads to genome instability and inactivation of oncosoppressor proteins and 
eventually tumorigenesis. Cells derived from a murine brain tumor induced by JCV 
injection have shown different resistance to ionizing radiation. We cultured these 
BSB8-RR cells and characterized them comparing to the radiation sensitive BSB8 
cells. Using MTT assay we showed a resistance to radiation to these cells, compare 
to the BSB8. We then performed cell-cycle analysis, colony formation assay e soft 
agar growth assay and we showed that BSB8-RR grow faster and they are more 
tumorigenic. Since we saw a decrease in the level of large T antigen expression in 
BSB8-RR, compared to BSB8, we hypothesized an involvement of large T antigen 
in DNA repair. Using DNA repair assays such as NHEJ and homologous 
recombination, we suggested that BSB8-RR cells may be resistant to radiation 
because they have increased homologous recombination activity, compared to the 
BSB8 cells. We suggested that this increase is due to the lower expression of large 
T antigen in BSB8-RR, that has been previously reported as inhibitor of homologous 
recombination. In conclusion, our data showed a more aggressive phenotype of 
BSB8-RR cells and a resistance to radiation that we suggested is due to the lower 
level of large T antigen in these cells, compared to BSB8.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	
	
SOMMARIO 
JCV è poliomavirus di piccole dimensione, nudo, con capside icosaedrico 
contenente un genoma a DNA circolare a doppio filamento. Il suo genoma si divide 
in geni precoci e tardivi, separati da una regione di controllo non codificante (NCCR) 
contentente il promotore, l’origine di replicazione (ORI) e gli elementi enhancer. I 
geni precoci codificano per la proteina T grande, la proteina t piccola e tre diverse 
proteine T’ T’135, T’136 and T’165. I geni tardive codificano per le proteine strutturali 
VP1, VP2 e VP3 e la proteina non strutturale agnoproteina. JCV replica solo 
nell’uomo. Le cellule non permissive non sono  in grado di supportare la replicazione 
virale o l’espressione delle proteine tardive. In queste cellule viene osservata solo la 
la trascrizione dei geni precoci, come ad esempio la proteina T grande. Questo porta 
ad una instabilitá genica ed all’inattivazione di oncosoppressori che infine portano a 
tumorigenesi. Cellule derivate da un tumore murino indotto da iniezione di JCV 
hanno mostrato resistanza alle radiazioni. Abbiamo coltivato queste cellule 
denominate BSB8-RR e le abbiamo caratterizzate, confrontandole con le BSB8, 
cellule sensibili alle radiazioni. Utilizzando il saggio di MTT abbiamo mostrato la 
resistenza alle radiazioni di queste cellule, rispetto alle BSB8. Abbiamo poi svolto 
analisi del ciclo cellulare, saggio di formazione di colonie e crescita su soft agar e 
abbiamo dimostrato che BSB8-RR crescono piu’ velocemente e sono piu’ 
tumorigeniche rispetto alle BSB8. Avendo visto una diminuzione del livello di 
espressione della proteina T grande in BSB8-RR rispetto alle BSB8, abbiamo 
ipotizzato un ruolo della proteina T grande nel riparo del DNA. Abbiamo utilizzato 
due assay per studiare il riparo del DNA, il non-homologous end joning (NHEJ) e la 
ricombinazione omologa (HR) e abbiamo mostrato che le BSB8-RR riparano il DNA 
con una percentuale piu’ alta di ricombinazione omologa rispetto a BSB8 e questo 
potrebbe essere il motivo per cui sono resistenti alle radiazioni.  
Concludendo, i nostri dati mostrano un fenotipo più aggressivo delle cellule BSB8-
RR e una resistenza alle radiazioni che noi suggeriamo sia dovuta alla minore 
espressione della proteina T grande in queste cellule, rispetto alle BSB8.  
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1. INTRODUCTION 
1.1 Polyomavirus 
Polyomaviruses are small, naked tumor viruses categorized within the 
Polyomaviridae family with icosahedral capsids containing a circular, double-
stranded DNA genome. Polyomaviruses name derives from “poly-”, a Greek 
word meaning many, and “-oma”, that means tumor, because the first 
isolated member of this family was able to induce various tumors when 
injected into mice [1, 2]. Polyomaviruses can infect different species, 
comprising humans, mice, hamsters, birds and monkeys [3].  
Studying the phylogenetic associations within polyomaviruses, four genera 
have been delineated: Alphapolyomavirus, Betapolyomavirus, 
Gammapolyomavirus and Deltapolyomavirus. The studies were based on 
the amino acid sequence of the large tumor antigen, large T antigen, one of 
the early viral proteins [4]. Each family member has a restricted host range, 
in general members of the genera Alphapolyomavirus, Betapolyomavirus 
and Deltapolyomavirus infect mammals, while members of the genus 
Gammapolyomavirus infect birds [1]. 
The first polyomavirus was discovered in 1953 [5] and named the murine 
pneumotropic virus (MptV). In 1959 and 1962 other two similar viruses were 
discovered and named simian virus 40 (SV40) [6, 7] and baboon 
polyomaviruses (SA12) [8]. To date, thirteen polyomaviruses have been 
identified in humans (Table 1). The first two human polyomaviruses have 
been discovered in 1971, BK virus, isolated from the urine of a patient with 
renal transplant [9] and JC virus, isolated from the brain of a patient with 
progressive multifocal leukoencephalopathy [10]. BKV and JCV were named 
after the patients’ name (initials) involved in the discoveries.  
BKV and JCV are widely spread in the human population, about 90% of 
adults have specific antibodies directed against these two viruses [11].  
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The human polyomaviruses BK and JC are characterized by a genomic 
sequence homology of 75%, they are morphologically very similar to murine 
oncogenic polyomavirus (PyV) and they show a common ancestral to the 
monkey virus (SV40) [12].  
In the last decade, several studies have led to the identification of new 
members of the Polyomaviridae family. In 2007, a study conducted on 
nasopharyngeal samples from children with infections of the respiratory tract, 
led to the identification of a new human polyomavirus, called Karolinska 
Institute Polyomavirus (KIPyV) because of the place where it was 
discovered. This virus is phylogenetically related to the early genomic region 
of the other human polyomaviruses, but it has low homology with the late 
region [13]. 
Concurrent to the discovery of the KI virus, another group of researchers 
discovered a fourth human polyomavirus, named Washington University 
Polyomavirus (WUPyV). They were analyzing genomic sequences found in 
bronchial washings from patients with severe inflammation of the respiratory 
tract [14]. Following the sequencing of the entire WU genome, a homology 
has been found between the structural characteristics of the WUPyV genome 
and the other human polyomaviruses. Preliminary data showed a similarity 
in the genomic structure, phylogenetic and tropism between WUPyV and 
KIPyV, suggesting that these viruses belong to a different branch of the 
human polyomavirus family [15].  
One year after the discoveries of KI and WU viruses, Feng and his 
collaborators conducted a study on Merkel Cell Carcinoma (MCC), a rare but 
aggressive skin cancer, to understand the possible role of viral infections in 
this type of cancer. In the samples analyzed, they discovered the presence 
of transcripts of the large T antigen of a polyomavirus that was never 
described. They named this virus as Merkel Cell Polyomavirus (MCPyV) [16]. 
Analyzing the large T antigen sequence, it has been found the presence of 
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mutations that are thought to be implicated in the formation of truncated 
forms of large T antigen. These truncated forms maintain their domain for 
Rb-binding [17].   
Human polyomaviruses 6 and 7 were isolated in 2010 by Schowalter and 
colleagues in cutaneous tampons [18].  
Also in 2010 van der Meijden and his group discovered a human 
polyomavirus associated with trichodysplasia spinulosa in an 
immunocompromised patient, named TSPV [19]. 
The human polyomavirus 9 was isolated in 2011 from a patient with history 
of kidney transplantation and immunosuppressive therapy [20].  
The Malawi Polyomavirus was isolated in 2012 in feces samples of a healthy 
baby in Malawi and in diarrheal feces of an American child from St. Louis 
[21].  
The human polyomavirus 12 was first discovered in 2013 during a screening 
of samples from the gastrointestinal tract. It was mostly found in liver samples 
but also in the colon, in the rectum and in feces [22]. 
The STLP virus was isolated in 2013, it was also found in fecal samples from 
a healthy Malawians child [23]. 
The New Jersey polyomavirus is the last human polyomavirus discovered to 
date. It was isolated from epithelial cells of a patient who was undergone to 
pancreatic transplant. A group of researcher led by Lipkin, screened tissue 
samples from a patient that was presenting retinal blindness and vasculitic 
myopathy, symptoms derivable from viral causes. They discovered the 
presence of a fourteenth human polyomavirus [24]. 
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In Table 1 a list of the human polyomaviruses discovered until 2017. The 
year of first description and the isolation sites are listed, along with the 
genome size.  
 
  
Table 1. Human polyomaviruses information. (Adapted from Cook, 2016 [25]) 
1.2 JC virus 
The John Cunningham virus or JCV is a human polyomavirus belonging to 
the genus Betapolyomavirus [26]. It has a circular genome of around 5 kb, 
5130 bp for the Mad-1 strain [27], associated with cellular histone proteins 
(H2A, H2B, H3 and H4) and packaged into chromatin resembling cellular 
genomes called minichromosomes [28]. The JCV genome is divided into 
early and late genes, which are separated by a non-coding control region 
(NCCR). The NCCR contains the promoter, the origin of replication (ORI) 
and the enhancer elements [29].  
Early and late genes are transcribed in opposite direction: the early region is 
the first to be transcribed in a counter-clockwise direction, while late genes 
are transcribed in a clockwise direction (Figure 1) [30]. The early genes 
encode for large T antigen, small t antigen and three different T’ proteins 
Name First 
description
Genome 
size
Associated clinical diseases /      
isolation sites
References
JC (JVPyV) 1971 5,310 Progressive multifocal leukoencephalopathy Padget et al, 1971
BK (BKPyV) 1971 5,153 Kidney and bladder epithelium, nephritis Gardner et al, 1971
KI (KIPyV) 2007 5,040 Respiratory tract Allander et al, 2007
WU (WUPyV) 2007 5,229 Respiratory tract Gaynor et al, 2007
MCPyV 2008 5,387 Merkel cell carcinoma Feng et al, 2008
TSPV 2010 5,232 Trichodysplasia spinulosa-associated skin lesions van der Meijden et al, 2010
HPyV6 2010 4,926 Normal skin and skin tumors; serum and body fluids Schowalter et al, 2010
HPyV7 2010 4,952 Normal skin and skin tumors; serum and body fluids Schowalter et al, 2010
HPyV9 2011 5,026 Kidney and bladder epithelium Scuda et al, 2011
HPyV10 
(Malawi or 
MWPyV, 
MXPyV)
2012 4,927
Healthy stool, acute diarrhea Siebrasse et al, 2012;    
Buck et al, 2012;             
Yu et al, 2012
HPyV12 2013 5,033 Liver, gastrointestinal tract Korup et al, 2013
STLPyV 2013 4,776 Fecal Lim et al, 2013
NJPyV 2104 5,108 Vascular endothelium, muscle tissue Mishra et al, 2014
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called T’135, T’136 and T’165, that are T antigen splice variants [31]. The late 
genes comprise the structural proteins VP1, VP2 and VP3, and the non-
structural agnoprotein [32].  
JCV infects only humans, in fact it has been suggested that the large T 
antigen can interact only with the human DNA polymerase, at the level of 
viral early gene transcription and DNA replication. JCV tissue tropism is 
specific for human glial cells, kidney epithelial cells, and, with less efficiency, 
in B lymphocytes, as experimental animals and in vitro analysis suggested  
[33, 34]. 
 
Figure 1. Schematic representation of JCV Mad-1 genome organization. The early 
open reading frame proceeds from the NCCR in the counter-clockwise direction and 
the late open reading frame in the clockwise orientation. Proteins in the same reading 
frame are illustrated with the same colour. Start and stop sites are indicated. All 
transcripts are polyadenylated. Reprinted with permission [30].  
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1.2.1 Non-coding control region (NCCR)  
The non-coding control region or NCCR is the most variable portion of the 
viral genome and it contains the origin of replication (ORI), the TATA box, 
binding sites for the large T antigen and cellular transcription factors, the 
bidirectional promoters and the enhancers. It is described as the region 
between the large T antigen start codon (ATG) and the start of the region 
encoding the agnoprotein. Unlike the coding regions that are well preserved 
belong the polyomaviruses, the NCCR region is hypervariable [35].  
In a single infected person, it is possible to find the NCCR and multiple 
variants. JC virus can have an archetype NCCR or rearranged NCCR, 
depending on the structure. The transmitted form of the JC virus is believed 
to be the one with the archetype NCCR because it is mostly found in the 
urine of healthy or diseased individuals and rarely in the brain of patients with 
progressive multifocal leukoencephalopathy (PML) [36].  
The most variable region within the JC virus NCCR is the 98-bp tandem 
repeat region. JC virus can be divided into two classes: the class I viruses 
are described as viruses containing the 98-bp tandem repeat within the 
NCCR, for example the Mad-1 strain. The class II viruses are strains of JC 
virus that show differences from the NCCR of class I because of the presence 
of deletions and insertions [37].   
The archetype NCCR is divided into 6 regions named Box A (36 bp), B (23 
bp), C (55 bp), D (66 bp), E (18 bp) and F (69 bp). Each box contains binding 
sites for cellular transcription factors involved in viral transcription [38].  
The prototype NCCR is a variant isolated from tissues of patients with PML, 
it is a rearrangement of the archetypal sequence. The first original prototype 
is the Mad-1 strain, which contains one NCCR consisting of a 98-bp 
sequence A-C-E, repeated (A-C-E-A-C-E-F), with duplication of the TATA 
box and binding sites for specific cellular transcription factors. The TATA 
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boxes are important for the transcription of both early and late viral genes 
[39]. The absence of the boxes B and D in the Mad-1 strain is involved in the 
formation of binding sites for cellular transcription factors, including YB-
1/Purα and NF-1 [40]. 
 
 
Figure 2. JC virus archetype and prototype regulatory region sequences and host 
transcription factor binding sites. Modified and reprinted with permission [40]. 
 
1.2.2 Early proteins 
The size of the JCV early region is 2.4 kb, it encodes for large T antigen, 
small t antigen and three different T’ proteins. A common pre-messenger 
RNA (mRNA) precursor is alternatively spliced and transcribed into the early 
proteins. Large T antigen and its variants have multifunctional tasks, they 
can interact with both viral and host proteins and DNAs. These proteins are 
involved in viral transformation, gene regulation and replication and they are 
required for driving the host cell toward S phase [32, 41]. 
The large T antigen is the main regulatory protein of polyomaviruses. It is 
necessary for the initiation of viral DNA replication and it is able to auto-
regulate its own promoter and trans-activate the late genes [42].  
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The large T antigen is a protein of 688 amino acids and it can be structurally 
divided into different functional domains: 
- DnaJ domain that binds cellular Hsc70 and polymerase α; 
- LXCXE motif that binds specifically the proteins of pRb family, inactivating 
their functionality; 
- TPPK, threonine-proline-proline-lysine domain; 
- NLS domain, necessary for the protein nuclear localization signal; 
- Helicase domain; 
- p53 binding domain, that binds the p53 cellular suppressor protein.  
 
These domains are listed from the N-terminal to the C-terminal and shown in 
Figure 3 [43].  
 
 
Figure 3. Representation of large T antigen structure. Reprinted under the Creative 
Commons Attribution License [43] 
 
On both the N- and C-terminal, two phosphorylation domains of serine and 
threonine residues are located: they are essential for large T antigen function 
in viral DNA replication [44].  
The DnaJ domain, at the N-terminal of the large T antigen protein, and the 
LXCXE motif contribute to viral DNA replication, with a mechanism that is still 
unknown. The LXCXE motif binds the retinoblastoma protein (pRb) and the 
pRb-related proteins retinoblastoma-like protein 1 (RLB1) and 
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retinoblastoma-like protein 2 (RBL2) [45]. The binding of the large T antigen 
to the pRb disrupts the pRb/E2F complexes, allowing the release of the 
transcription factor E2F. Its release promotes cell cycle progression, 
stimulating the resting cells to enter the S-phase of the cell cycle (Figure 4A 
and 4B) [46].  
Following the DnaJ and the LXCXE domains, there is a threonine-proline-
proline-lysine (TPPK) domain. The phosphorylation of its threonine residue 
is important for the replication mediated by the large T antigen [47].  
C-terminal to the TPPK motif, there are a nuclear localization sequence 
(NLS), a DNA-binding domain (DBD) and a helicase domain. The NLS is 
important for the transport of the newly formed large T antigen proteins from 
the cytoplasm to the nucleus mediated by specific importins. The DBD and 
helicase domains are required for viral replication because they recruit 
cellular factors involved in DNA replication. The DBD can recruit protein such 
as the DNA polymerase-α catalytic subunit, the replication protein A complex 
and the DNA primase complex; the helicase domain recruits EP300, 
CREBBP, p53 and DNA topoisomerase 1 [47]. The helicase domain, in 
addition to recruit cellular proteins, binds precise regions of the origin of 
replication (ORI) in the NCCR. This binding permits the initiation of the viral 
replication [48]. The protein p53 is one of the protein that the helicase domain 
can bind: this binding results in the block of all the p53 downstream functions, 
for example the induction of apoptosis and the arrest of cell growth (Figure 
4C and 4D) [49].  
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Figure 4. Schematic representation of the role of large T antigen on host cell 
transcription. (A) In absence of mitotic signals, E2F remains attached to Rb and the 
transcription of E2F targeted genes is inhibited. (B) In the presence of large T 
antigen, it can bind to Rb, avoiding the formation of the complex E2F/Rb and 
permitting the entry of the host cell in mitosis. (C) In a normal cell, the p53 pathway 
is activated and it can promote the transcription of genes involved in DNA repair or 
apoptosis, such as MDM2, BAX and p21. (D) The presence of large T antigen and 
its direct binding to p53, prevents the binding between the p53 protein and the host 
cell DNA. Modified and reprinted with permission [50]. 
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The role of the small t antigen is not yet fully delineated. It has been 
demonstrated its importance in the JCV life cycle, because it has an active 
role in the induction of the cells to start the S phase of the cell cycle. In fact, 
the small t antigen interacts and inactivates the regulatory factors belonging 
to the Rb family and it sequesters the protein phosphatase 2 (PP2A) [51]. 
The inhibition of PP2A mediated by the small t antigen prevents the viral late 
agnoprotein dephosphorylation and this can be an important regulatory 
mechanism for JCV replication [52]. 
The T’ proteins (T’135, T’136, and T’165) were discovered in 1995 by 
Trowbridge and Frisque. At first, it was supposed they were products form 
the degradation of the large T antigen because they share with it a sequence 
homology equal to 132 amino acids [31].  
Then, it was discovered that the T' proteins are generated by alternative 
splicing of the mRNA coding for the large T antigen. Indeed, they share the 
DnaJ domain and LXCXE in the N-terminal portion, but they differ at the C-
terminal end because the T’ proteins have a different degree of 
phosphorylation. This difference affects the binding of the T' proteins with the 
members of the Rb family, such as pRb, p107 and p130, and with the Hsp70. 
In particular, this interaction results in the release of the transcriptional factor 
E2F that promotes the advancement of the cell cycle from G1 to S phase [53, 
54]. 
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Figure 5. Graphical representation of JCV early proteins, large T antigen (LT-Ag), 
small t antigen (Sm t-Ag) and T′ proteins (T′-135, T′-136 and T′-165) and some 
functional domains. Reprinted with permission with modification [54] 
 
1.2.3 Late Proteins 
The size of the JCV late region is 2.3 kb, it encodes for three structural 
proteins, the major VP1 and the two minor VP2 and VP3, and the 
agnoprotein. Analogously to the early region, a common late pre-mRNA 
precursor is alternatively spliced and transcribed into the late proteins. The 
ORFs of the late proteins overlap: VP1 is a protein composed of 354 amino 
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acids, its ORF is located at the 3’ end of the late protein region. The ORFs 
for VP2 and VP3 are located between the 3’ end of the agnoprotein ORF and 
the 5’ end of the VP1 ORF. VP2 is 344 amino acids and VP3 is arranged 
from the 225 amino acids at the C-terminal of VP2. Agnoprotein is the 
smallest protein, it is constituted of 71 amino acids and its ORF begins at 
nucleotide 277 and terminates at nucleotide 492.  
The VP1 protein is the main viral capsid protein. For each pentamer of VP1 
there is a single molecule of VP2 or VP3, in order to form an individual 
capsomere that contains a pore at the five-fold axis of symmetry. It is 
probable that the pore is occupied by the C-terminus of VP2. The VP1 C-
terminals extend to anchor together adjacent capsomeres and to form the 
entire capsid of 72 pentamers [55-57]. The VP1 protein contains the epitopes 
recognized by the host immune system and it is involved in the identification 
of the cellular receptors and infection of the target cells [58, 59].  
VP2 and VP3 are the minor capsid proteins, they have a role in the transport 
of the virus to the nucleus and its scavenging [60, 61]. They are also involved 
in the assembling of the capsid, in fact it has been demonstrated that the 
binding between VP2 and VP3 proteins, chaperone Hsp70 and large T 
antigen leads to the formation of deposits of pre-virions within the nucleus of 
infected cells. Specifically, late proteins VP2 and VP3, associated with 
Hsp70, can interact with large T antigen in the cytoplasm or in the nucleus. 
This interaction induces a conformational change in the large T antigen that 
increases its affinity for the viral origin of replication followed by new DNA 
synthesis. Newly made DNA is immediately caught by the VP2 and VP3 
proteins that can start the virion assembly process. Subsequently, the 
nucleocapsids are covered by the VP1 protein and they become mature 
virions [54]. 
Agnoprotein is active during the last phase of JCV cellular infection. Its 
function has not been well understood yet. It has been hypothesized that it 
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could be a viroporine, supporting the release of the virus from the cells [62]. 
Agnoprotein also interacts with large T antigen in order to reduce the levels 
of viral replication to promote the translation of the late transcripts and the 
formation of mature virions. Some authors have shown that agnoprotein can 
be implicated in tumorigenesis. In fact, in the non-permissive cells infected, 
agnoprotein acts in cooperation with large T antigen in order to alter the 
regulation of cellular metabolic by the host cell becoming transformed. In 
particular, it would contribute to the development of mutations at the level of 
genomic DNA, blocking the activity of the cellular proteins involved in the 
mechanisms of DNA repair [63-66]. 
1.2.4 Infectious lifecycle 
The infectious lifecycle of JC virus is divided into early and late stages. The 
early stage starts with the interaction of the virus with the surface of the host 
cell and lasts until the beginning of viral DNA replication. The late stage 
comprises all the following events that lead to the assembly of new virions 
and ends with the release of viral progeny.  
The early stage starts with the JC virus attachment to the cell surface 
receptors, in particular the serotonin receptor 5HT2A and alpha (2–6)-linked 
sialic acid [67]. The attached virus particles enter the cells through clathrin-
mediated endocytosis [68, 69]. Following internalization, the virus is being 
transported to the Rab5+ early endosomes, translocated within the 
endoplasmic reticulum and released into the cytoplasm in order to move 
towards the nucleus. Entry into the nucleus involves interaction with nuclear 
pore complexes [30]. The following step is the expression in the nucleus of 
the viral early genome and then the alternative splicing of the viral transcripts. 
After splicing events, the early proteins are transported back to the 
cytoplasm, where they are translated into large T antigen, small t antigen and 
T’ proteins. Large T antigen is transported back to the nucleus where it can 
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directly recruit the host cell DNA polymerase complex to the viral ORI, in 
order to initiate bi-directional viral DNA synthesis and trans-activate the viral 
late promoter. At this point, the production of the three structural capsid 
proteins, VP1, VP2, and VP3, and the regulatory agnoprotein starts [70, 71]. 
It has been shown that also the small t antigen has an important role in JCV 
replication [52]. Once the capsid proteins are translated, they are transported 
back to the nucleus, where the encapsidation process starts: the proteins are 
sequentially added to one another and the viral genome can be packaged 
into the capsids. The last and final step is the release of the virions from 
infected cells, probably upon the lysis of the infected cells [72].  
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Figure 6. Chronological events during JCV life cycle. (1) Binding of virus to the 
receptors on the cell surface; (2) entry in the cell by clathrin-mediated endocytosis; 
(3) uncoating of virions, both in endoplasmic reticulum or in the nucleus and nuclear 
transport; (4) transcription of early genome region; (5) translation of early regulatory 
proteins; (6) import of Large T antigen (LT-Ag) into nucleus to start viral DNA 
replication and activation of late genome transcription; (7) replication, (8) 
transcription and (9) translation of viral late genome; (10) import of capsid proteins 
in the nucleus; (11) assembly of viral progeny in the nucleus; (12) release of virions 
from infected cells. Reprinted with permission [72].  
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1.2.5 JCV associated diseases in the central nervous system 
Progressive multifocal leukoencephalopathy or PML is a rare but fatal brain 
demyelinating pathology that results from the JCV lytic infection in 
oligodendrocytes. These cells produce myelin sheets, which wrap around the 
axons of the neurons to support the transmission of the neuronal current. 
The infection causes oligodendrocytes death and, sub-sequentially, lack of 
myelin. This leads to axonal dysfunction and eventually neurons death. The 
death of both oligodendrocytes and neurons in the CNS and their loss result 
in the formation of small plaque. PML lesions are multifocal and they affect 
the white matter. Areas where these plaques are formed merge and form 
lesions, as the disease develops. The result is the death of the individual [3].  
PML symptoms are: motor dysfunction, visual defects and speech 
impairment. MRI to visualize multifocal lesions is essential in diagnosis 
because these symptoms are not specific for PML. MRI is followed by 
research of JCV DNA and/or proteins in the cerebrospinal fluid and brain 
biopsies. The first neuropathological description of PML has been reported 
in 1958 by Astrom and colleagues, where they analyzed brain tissue from 
patients with chronic lymphatic leukemia and Hodgkin's disease [73]. PML 
etiology was unknown until the discovery of the presence of viral particles in 
cerebral lesions typical of PML [74]. These were then isolated in cultures of 
fetal human brain in the 1971 by Padgett and colleagues. The cerebral tissue 
used to isolate the virus was taken from the patient John Cunningham, JC, 
whose initials gave the name to JC virus [10]. 
Between the 1971 and the early years of the 80s, only around 200 cases had 
been reported, all connected with lymphoproliferative disorders [75]. PML 
became more prevalent after the AIDS epidemic, from all HIV-positive 
patients, around 3% developed PML [76]. The major cause of developing 
PML in AIDS patients is believed to be linked to the decrease in CD4+ T cells.  
18	
	
These cells are necessary for the maintenance of CD8+ T cells, the most 
important cells in the immune control of JCV infection [77]. Furthermore, it is 
possible that the interactions between JCV and HIV may contribute to the 
development of PML. In particular, HIV protein Tat may stimulate JCV 
promoter [78, 79].  
PML has been diagnosed also in individuals under monoclonal antibody 
therapy for treating autoimmune diseases or lymphoproliferative disorders. 
Four monoclonal antibodies have been associated with PML: natalizumab, 
efalizumab, rituximab and infliximab. These drugs cause the depletion of 
mature B cells in the periphery, with the consequent recruitment of immature 
B cells from the bone marrow and the potential spread of the latent virus in 
the brain [30]. 
There is currently no effective therapy able to neutralize this pathology. 
Natalizumab mechanism to increase the risk of developing PML is not yet 
known. It has been theorized that the low immune-surveillance of the CNS 
and the increased presence of B cells and CD34+ progenitor cells together 
can be advantageous for JCV viral replication [49].  
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Figure 7. (A) Gross examination of JCV- induced lesions occurring at the subcortical 
white matter. A coronal section of the frontal lobe of the brain from a PML patient is 
shown. (B) Apparent myelin loss, as result of JCV infection of oligodendrocytes, is 
made detectable by Luxol blue staining (40×). Demyelinated areas are visibly 
distinguishable as white plaque areas. (C) Hematoxilin and Eosin staining of the 
brain sections from a PML patient. Infected oligodendrocytes are indicated with a 
round dark staining of the eosinophilic inclusion bodies (arrow head). An arrow points 
to an infected astrocyte (400×). Reprinted with permission from [80]. 
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After JCV discovery in 1971, JCV was thought to be able to infect only 
oligodendrocytes and astrocytes in the brain white matter, neurons were not 
considered susceptible to infection [81]. In 2003, a group of researcher has 
demonstrated a productive JCV infection of cerebellar granule cell neurons 
[82] and in 2005, a disease called JCV granule cell neuronopathy (JCV GCN) 
was described [83]. In 2009, a grey matter disease has been described in a 
HIV-negative patient presenting lung cancer. This disease has been named 
JCV encephalopathy (JCVE), and it is characterized by a productive infection 
in the cortical pyramidal neurons [84].  In 2014, a fatal case of JCV meningitis 
(JCVM) was described. It was found in an HIV-negative patient with a very 
high JC viral load in the cerebrospinal fluid and productive infection in 
leptomeningeal cells [85]. This specific tropism for cerebellar granule cell 
neurons is caused by a JCV variant with a small deletion in the VP1 protein. 
This infection results in cerebellar atrophy and associated dysarthria, 
appendicular, and gait ataxia [86].  
JCV granule cell neuronopathy can be manifested both in concomitance or 
not with PML [82, 83] and it has been described in both HIV-positive and HIV-
negative patients [87-89]. The JCV GCN disease is characterized by 
destruction of cerebellar granule cells. This leads to a subacute or chronic 
cerebellar dysfunction with several symptoms: ataxia, dysarthria and motor 
incoordination. MRI shows cerebellar atrophy and changes in the white 
matter in the cerebellum and brainstem [90]. The definitive diagnosis is 
based using PCR to detect JCV DNA in CSF, cerebellar biopsy displaying 
JCV infection of granule cell neurons or immunohistochemistry using an 
antibody against T antigen in combination with a neuronal marker, such as 
NeuN or MAP-2. The infected granule cell neurons are expected to have a 
hyperchromatic aspect with enlarged nucleus [83, 91]. The JCV GCN therapy 
is identical to the one for PML [92]. 
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In JCV encephalopathy, JCV infection mainly implicates cerebral pyramidal 
neurons and astrocytes in the cortical grey matter and grey-white junctions. 
Viral proteins have been found in the nuclei, cytoplasm and axons of 
neurons, suggesting that JC virus may migrate through axons of infected 
neurons and spreads in the brain. It is more common to find large T antigen 
than VP1 in infected neurons, so probably in the cortical pyramidal neurons, 
the JCV infection is abortive. Wüthrich and colleagues [84] described the first 
case of JCV encephalopathy in a patient who presented multiple cortical 
lesions, aphasia, and progressive cognitive decline. RM showed lesions at 
the level of the grey substance and the viral genome was found through PCR 
in the liquor. The diagnosis was finally confirmed by the histological 
examination that showed a JCV correlated lytic infection of cortical pyramidal 
neurons and astrocytes. 
Unlike PML, in JCV meningitis (JCVM) there are no focal lesions of the white 
matter and the MR shows only a slight dilatation of the cerebral ventricles. 
Numerous cases have been documented describing JCV as the only 
pathogen present in the CSF of patients with typical meningeal symptoms. It 
is not yet clear whether this clinical picture is due to a primary viral infection 
or to a reactivation of the virus. The diagnosis is confirmed by the research 
of JCV viral genome in the liquor in the absence of all other neurotrophic 
viruses. Therapy, even in this case, it is the same as the one for PML [92]. 
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1.2.6 JCV and tumors 
When the expression of early genes is followed by the replication of viral 
DNA and expression of late genes, the result is a productive infection. One 
example is the infection of oligodendrocytes, which are permissive to the lytic 
infection of JCV and are destroyed during the infectious process, leading to 
the PML. However, other scenarios are also possible. In the case of non-
permissive cell infection, only the expression of early genes is observed. 
Such cells are not able to support neither viral replication nor the expression 
of late genes. In this situation, the expression of large T antigen leads to the 
inactivation of oncosuppressors and to the deregulation of signalling 
pathways or genome instability, which can contribute to cellular 
transformation (Figure 8) [33]. 
 
 
Figure 8. Mechanisms of JCV T-antigen-mediated cellular transformation or 
demyelination. Reprinted with permission [33]. 
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The oncogenic potential of Polyomavirus JC has been extensively 
demonstrated in vitro in non-permissive cells. In these cells, the viral 
replication cycle is not completed, pushing the cell into transformation. The 
factors contributing to the permissiveness can be several, such as tissue of 
origin, point of development, or state of differentiation. This can be observed 
in the same oligodendrocytes: the mature oligodendrocyte can totally support 
a lytic infection while an undifferentiated oligodendrocyte can not. The 
undifferentiated oligodendrocyte might only allow the expression of the large 
T antigen, leading to the cell transformation and development of an 
oligodendroglioma [33]. 
As described above, the large T antigen is the major actor in cell 
transformation, because its several domains cooperate in binding and 
inactivating cellular proteins that typically stop the entry into S phase. JCV 
large T antigen drives the cell cycle from G1 into S phase, promoting cell 
transformation in non-permissive cells [2]. This transition is the result of the 
binding between the LXCXE domain on large T antigen and proteins 
belonging to the Rb tumor suppressor family [45, 93, 94]. The binding 
between large T antigen, p53 and pRb family leads to the inactivation of 
cellular tumor suppressors protein and then uncontrolled cell growth. The 
connection between large T antigen and p53 removes the ability of the 
cellular protein to enhance transcription of p21/WAF-1, an inhibitor of cyclin 
kinases. In normal situations, a reduction in the kinase activity of G1/S 
cyclins:cdks keeps pRb in a hypophosphorylated state. In this state pRb is 
active and can sequester E2F, an S phase specific transcription factor. The 
binding between large T antigen and pRb can release E2F from the pRb:E2F 
complex so it can promote unscheduled transcription of S phase genes 
(Figure 9) [95].  
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Figure 9. Mechanisms of the p53, pRb tumor suppressor pathways. Reprinted with 
permission [95]. 
 
JCV large T antigen can also bind other cellular proteins, such as insulin 
receptor substrate 1 (IRS-1), β-catenin, the neurofibromatosis type 2 gene 
product and the antiapoptotic protein survivin [96-100]. IRS-1 is a membrane 
associated tyrosine kinase, its activation causes cell proliferation and 
activates antiapoptotic signals. Large T antigen can bind IRS-1, causing its 
translocation into the nucleus. This translocation is important in one of the 
mechanisms involved in DNA repair, the homologous recombination (HR). 
Normally, the Insulin Growth Factor-I Receptor (IGF-1R)/IRS-1 signalling 
pathway supports HR because of a direct binding between Rad51 and hypo-
phosphorylated IRS-1 in the cytoplasm. When IGF-1R is being stimulated, 
IRS-1 becomes phosphorylated and loses the capacity to complex Rad51. 
This protein can now translocate into the nucleus, where it is involved in 
25	
	
mechanisms that support HR DNA repair [101, 102]. Large T antigen inhibits 
HR because it supports the binding between Rad51 and IRS-1 in the 
nucleus. This leads to an accumulation of DNA mutation and eventually 
malignant phenotype [96, 101, 103]. Furthermore, IRS-1 is the key 
component of IGF-1 signalling pathway. The binding with large T antigen 
leads also to abnormal phosphorylation and activity of MAPK and PI3K, 
leading to tumor development (Figure 10) [104].  
 
 
Figure 10. Mechanisms of the IGF-1 signalling pathways. Reprinted with 
permission [95]. 
 
Several studies have demonstrated the involvement of Wnt signalling in 
various cancers associated with JCV. It was theorized that JCV was involved 
in the deregulation of the Wnt signalling pathway, in particular the large T 
antigen binding with β-catenin, a protein belonging to the Wnt pathway. Large 
T antigen induces the stabilization of β-catenin, which increases in protein 
level and translocates into the nucleus. Here, β-catenin is able to induce the 
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transcription of C-Myc and cyclin D1, proteins involved in the cell life cycle 
(Figure 11) [105].  
 
 
Figure 11. Mechanisms of the Wnt signalling pathway. Reprinted with permission 
[95]. 
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In Figure 12 a schematic summary of the molecular mechanisms of cell 
transformation mediated by large T antigen.  
 
 
Figure 12. Molecular mechanisms of cell transformation mediated by large T 
antigen. Reprinted with permission [2]. 
 
1.2.7 JCV-Induced Mouse Medulloblastoma 
In order to understand the tissue specificity of JCV and its potential role in 
inducing diseases, in 1999, Krynska et al [106] generated a transgenic 
mouse containing the early region of JCV. Using this mouse model, the same 
group, in 2000 [107], described two distinct sub-populations of cells. These 
sub-populations were derived from the tissues taken from this animal model, 
that is very related to the human medulloblastoma.  
As shown in Figure 13, the two populations of cells show a very different 
morphological appearance.  
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Figure 13. Morphological appearance of clonal cell lines derived from a mouse 
medulloblastoma; From A through D: BS-1a, BS-1b, BS-1c and BS-1f, four clonal 
cell lines that exhibit a moderate degree of cytoplasm and a process-bearing 
morphology. From E through H: BS-1B7, BS-1B8, BS-1B13 and BS-B14, four cell 
lines with scant cytoplasm and shorter processes. Reprinted with permission [107]. 
 
In this paper, the authors described a population of cells that was T antigen 
negative and a population that was T antigen positive. They developed four 
different cells lines for each population and named BS-1a, BS-1b, BS-1c and 
BS-1f the T antigen-negative cells, BS-1B7, BS-1B8, BS-1B13 and BS-B14 
the T antigen-positive cells. Figure 14 shows the immunohistochemical 
staining for JCV T antigen, neuronal marker filament, synaptophysin and 
GFAP in BS-1a and BS-1B7. 
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Figure 14. Immunohistochemical evaluation of BS-1a (A through D) and BS-1B7 (E 
through H). Panel A and E reveal the presence of JCV T antigen in nuclei of BS-1B7 
cells but the absence in nuclei of BS-1a. Positive staining for neuronal cellular marker 
(B and F) and synaptophysin (C and G) is observed. Negative immunoreactivity for 
glial marker GFAP (D and H). Reprinted with permission [107]. 
 
After characterization, the authors studied the tumorigenicity of these cells. 
They observed that all the T antigen-positive cells were able to produce large 
tumors in nude mice, while only one T antigen-negative cell line was able to 
produce a small tumor. 
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2. AIMS OF THE STUDY 
The human polyomavirus JC (JCV) is a member of the Polyomaviridae 
family, isolated for the first time in 1971 from the brain of a patient with 
progressive multifocal leukoencephalopathy [10]. JCV infects only humans, 
and within human cells it has a tissue-specific tropism. JCV infection in non-
permissive cells leads to a transforming phenotype, with the expression of 
early protein large T antigen [33, 34].  
Previously, two population of cells derived from a murine brain tumor induced 
by JCV injection have been characterized [106, 107]. This tumor is correlated 
to the human medulloblastoma, a very aggressive and invasive tumor of the 
cerebellum. It is one of the most common neoplasms in children. Cells 
characterized within the two populations were either T antigen-negative or T 
antigen-positive. 
Ionizing radiations are one of first treatment in tumor therapies. Since the 
populations were derived from a tumor, we culture this two populations of 
cells and we irradiated them to study their viability after irradiation. 
Surprisingly, after radiation treatment, we noticed that some of the T antigen-
positive cells were still viable.  
Aims of this thesis are: characterize the radiation resistant cells, named 
BSB8-RR (Radiation Resistant) and the radiation sensitive cells, named 
BSB8. After characterization, we aim to understand if JCV T antigen has an 
effective role in the resistance to radiation. In fact, radiations cause DNA 
double strand breaks and previously, it has been demonstrated a link 
between JCV T antigen and mechanisms for repairing DNA [101].  We would 
like to understand if the expression level of large T antigen changes among 
BSB8 and BSB8-RR and if this change can affect the resistance to radiation.    
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3. MATERIAL AND METHODS 
3.1 Cell lines and cultures 
The mouse medulloblastoma T-antigen-positive, BSB8, as well as T-antigen-
negative, BS1A were previously described [106]. BSB8-Radiation Resistant 
(RR) were developed irradiating BSB8 cells with 6-Gy energy and culturing 
resistant cells arose. BS1A, BSB8 and BSB8-RR cells were grown in 
Dulbecco’s Modified Eagle’s Medium (DMEM) containing 5% heat-
inactivated FBS and 100 µg/ml penicillin/streptomycin. All the cells were 
maintained at 37°C in a humidified atmosphere with 7% CO2. 
3.2 MTT assay for cell viability 
BSB8 and BS1A cells were plated in a concentration of 3 x 105 cells/well in 
6-well tissue culture plates and irradiated with a different amount of ionizing 
radiation (3-Gy, 6-Gy or 12-Gy). Forty-eight hours after treatment, cells were 
incubated with 1 ml of MTT (3-(4 5-dimethylthiazol-2-yl)-2 5-
diphenyltetrazolium bromide) at 0.5 mg/ml working solution for 2 hours at 
37°C. The converted insoluble purple formazan was solubilized with 1 ml of 
acidic isopropanol (0.004 M HCl in isopropanol). The absorbance of the 
converted formazan was measured at a wavelength of 570 nm with a 
background subtraction at 650 nm. BSB8 and BSB8-RR were plated in 6-
well tissue culture plates and irradiated with ionizing radiation (6-Gy). Forty-
eight and seventy-two hours after treatment they were processed for MTT 
assay as described. 
3.3 Western blotting 
Whole cell protein extracts were washed with PBS and lysed with TNN lysis 
buffer (40 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM DTT, 1 mM EDTA, 1% 
NP40, and 1% protease inhibitors cocktail). Protein concentrations were 
quantified using Bradford reagent. Protein extracts were then heated to 95°C 
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for 5 min and resolved through sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE). Then, they were transferred to nitrocellulose 
membranes in a transfer buffer containing 25 mM Tris base (pH 7.4), 200 
mM glycine, and 20% methanol. After transfer, membranes were blocked for 
30 min at room temperature with 10% non-fat dry milk in 1X phosphate-
buffered saline containing 0.1% Tween-20 (PBST). After blocking, 
membranes were incubated with primary antibodies overnight at 4°C. The 
membranes were subsequently washed three times with PBST and 
incubated with secondary antibodies at a dilution of 1:5000 for 1 h at room 
temperature. After secondary antibodies incubation, membranes were 
visualized with an Odyssey CLx Imaging System (LI-COR).  
3.4 Cell cycle 
BSB8 and BSB8-RR were harvested at three different time point: 0h, 12h, 
24h after FBS deprivation for twenty-four hours. Cells were washed with 
PBS, resuspended in 1 ml of PBS and added drop-wise to 4 ml of 88% 
ethanol to fix them, in a final concentration of 70% ethanol. Cells were then 
washed with PBS, resuspended in 300 µl of PBS and incubated with 10 µg/ml 
of propidium iodide and 100ug/ml solution of RNase A at 37°C for 30 minutes 
in the dark. After incubation, cells were cooled at 4°C and data were acquired 
using a Guava EasyCyte Mini flow cytometer (Guava Technologies). 
3.5 Colony formation assay 
To assess tumorigenesis, BSB8 and BSB8-RR were transfected with 
pcDNA3.1 (+) and after twenty-four hours harvested and replated in 100-mm 
dishes.  Cells were kept in DMEM complete medium with G418 for selection 
until colonies formation. To count the number of colonies, cells were fixed 
and stained with a solution of with 0.1% crystal violet in 20% (vol/vol) 
aqueous methanol.  
33	
	
3.6 Soft agar growth 
BSB8 and BSB8-RR were transfected with pcDNA3.1 (+) and after twenty-
four hours harvested and seeded in 60-mm dishes containing 2 mL of a 0.3% 
agarose suspension in DMEM complete medium with G418. Plates were 
then incubated at 37°C for three weeks.  
3.7 Nonhomologous end joining assay for double strand DNA break 
repair 
The nonhomologous end joining (NHEJ) assay was performed by a 
modification of the method of Baumann [108] as previously described [109]. 
Nuclear extract of BSB8 and BSB8-RR was prepared as follows. Cells were 
harvested, washed with ice-cold PBS, resuspended in ice-cold hypotonic 
lysis buffer, denominated Buffer A (10 mM HEPES pH 7.9, 10 mM KCl, 1.5 
mM MgCl2, 1 mM DTT and protease inhibitors), and left on ice for fifteen 
minutes. Then, lysates were centrifuged at 1,800 g for ten minutes and the 
supernatants were aliquoted as A1-cytoplasmic extract. Cell pellets were 
resuspended in ice-cold Buffer A and homogenized to 90% cell lysis and 
centrifuged at max speed for twenty minutes. Supernatants were aliquoted 
as A2/S100-Cytosolic extract. Cell pellets were resuspended in ice-cold 
hypertonic nuclear lysis buffer, denominated Buffer C (20 mM HEPES pH 
7.9, 0.6 M KCl, 1.5 mM MgCl2, 0.2 mM EDTA, 25% (v/v) glycerol, 1 mM DTT, 
0.5 mM PMSF and protease inhibitors). After forty-five minutes under 
shaking at 4°C, the nuclear lysates were centrifuged at max speed for thirty 
minutes. Supernatants were aliquoted as nuclear extract and dialyzed 
overnight against buffer containing 25 mM Tris HCl (pH 7.5), l mM EDTA, 
10% glycerol (vol/vol) and protease inhibitors. 
The NHEJ assay was performed as follows. pBlueScript(KS+) was linearized 
by restriction endonuclease digestion in order to have four nucleotide 5′ 
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overhang at one end, using BamHI, and the other end blunt with EcoRV. The 
resulting 3 Kb linear DNA was used as DNA substrate for the end-joining 
reactions. Reactions were set up in 25 mM Tris OAc (pH 7.5), 100 mM KOAc, 
10 mM MgOAc, 1 mM DTT, 2 mM ATP and 200 mM dNTPs as reaction 
buffer. 50 μg of nuclear extracts from BSB8 or BSB8-RR was added to the 
reaction buffer. The reactions were then incubated for five minutes at 37°C 
before the addition of 400 ng of DNA substrate and then for one hour at 37°C. 
DNA products were deproteinized by treatment with proteinase K and 
analyzed by electrophoresis through a 0.7% agarose gel.  
3.8 Homologous recombination for double strand DNA break repair 
The homologous recombination (HR) events were measured by a 
modification of a method previously described [110]. For the transient 
transfection, BSB8 and BSB8-RR cells were electroporated with different 
amount of an expression plasmid containing DR-GFP recombination 
substrate denominated pDRGFP, pCBASceI expression plasmid encoding I-
SceI endonuclease and pDsRedl-Mito (Clontech, Paolo Alto, CA). The 
expression of I-SceI causes a double strand break (DSB) in the specific 
restriction site included in the DR-GFP cassette and HR events can restore 
the functional GFP expression. The co-transfection with pDsRedl-Mito, a 
plasmid that encodes for a red fluorescent protein with a mitochondrial 
localization, was used to calculate the efficiency of the transfection. Seventy-
two hours after electroporation, cells were harvested and GFP and RFP 
expression was detected and quantified using Guava EasyCyte Mini flow 
cytometer (Guava Technologies). Stable cells for DRGFP were created as 
follow: BSB8 and BSB8-RR were electroporated with pDRGFP. Forty-eight 
hours after transfection cells were harvested and replated in 100-mm dishes 
with DMEM and puromycin for selection. BSB8-DRGFP and BSB8-RR-
DRGFP were then electroporated with different amount of pCBASceI and 
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pDsRedl-Mito. After five days, cells were harvested and GFP and RFP 
expression was detected and quantified. The HR efficiency was established 
as the percentage of cells showing both green nuclear fluorescence and red 
mitochondrial fluorescence versus cells showing only red fluorescence.  
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4. RESULTS 
4.1 Impact of large T antigen on resistance to radiation in JCV 
induced tumors  
4.1.1 Radiation induces apoptosis in BSB8 cells 
First, we examined whether ionizing radiation has an impact on BSB8 and 
BS1A cells viability. Cells were irradiated with three different radiation doses: 
3-Gy, 6-Gy and 12-Gy and MTT assay was performed seventy-two hours 
after treatment. As shown in Figure 15 panel A, radiations had no impact on 
BS1A cells, but a reduction in BSB8 viability was observed. The reduction 
was visible even at the lowest dose of radiation used. Since MTT assay does 
not discriminate between apoptosis and necrosis, we performed a western 
blot to check the expression levels of proteins involved in apoptosis and 
autophagy, such as caspase-3 and cleaved caspase-3, Bag3 and LC3. BS1A 
and BSB8 cells were irradiated with two different radiation doses: 6-Gy and 
12-Gy. Seventy-two hours after treatment, whole cell protein content was 
extracted and analyzed. As we can see in Figure 15 panel B, there is an 
increase in the expression level of Cleaved Caspase-3 and a slight decrease 
of Bag3 level in BSB8 cells, compared to BS1A. This means that radiations 
stimulate apoptosis in BSB8 but not in BS1A, in a dose dependent manner. 
Autophagy was stimulated in both BSB8 and BS1A cells, as demonstrated 
by the conversion from LC3-I to LC3-II. Looking at the level of large T antigen 
in BSB8 after radiation, we observed that treatment reduces the expression 
level of this protein, suggesting that it may have a role in the sensibility to 
ionizing radiation.  
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Figure 15. Effect of radiation on apoptosis and autophagy. Panel A: MTT assay of 
BS1A and BSB8 cells after treatment with ionizing radiation. Panel B: Expression of 
proteins involved in apoptosis and autophagy in BS1A and BSB8 cells after radiation 
treatment.  
 
4.1.2 A small population of BSB8 cells survives after radiation 
While performing our experiments, we observed that 10% of BSB8 cells were 
still viable seventy-two hours post-radiation. We then decided to culture 
these cells because we wanted to understand why they were still viable and 
we denominated them as BSB8-Radiation Resistant (BSB8-RR). In panel A 
of Figure 16 we showed the outline we used to culture these RR cells. We 
first irradiated BSB8 cells for MTT assay. We noticed some cells were still 
viable and we cultured them for some time and we confirmed the resistance 
to the radiation of these cells performing another viability assay after 
radiations. The validation of the resistance to radiation by BSB8-RR is shown 
in panel B and C of Figure 16: BSB8 and BSB8-RR were irradiated with a 
radiation dose of 6-Gy and a MTT assay was performed forty-eight and 
seventy-two hours after treatment. At forty-eight hours (panel B), there is no 
difference in cells viability between control and irradiated cell in both BSB8 
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cells and BSB8-RR cells. At seventy-two hours, irradiated BSB8 cells show 
a strong decrease in their viability, compare to the BSB8 cells not irradiated 
(panel C). BSB8-RR viability is not affected by radiation: in fact, even after 
seventy-two hours, viability of BSB8-RR irradiated is comparable to BSB8-
RR not irradiated (control) viability. 
 
Figure 16. BSB8-RR cells show resistance to second radiation. Panel A: Outline of 
BSB8 and BSB8-RR viability assay after treatment with radiation. Panel B: MTT 
assay on BSB8 and BSB8-RR control or irradiated with dose of 6-Gy at forty-eight 
hours after radiation. Panel C: MTT assay on BSB8 and BSB8-RR control or 
irradiated with dose of 6-Gy at seventy-two hours after radiation. 
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4.1.3 BSB8-RR cells express reduced levels of JCV early proteins 
Given this ability to resist radiation, we then investigated the role of JCV early 
proteins, large T antigen and small t antigen, in BSB8-RR cells. First, we 
extracted whole cell protein from BS1A, BSB8 and BSB8-RR and we 
determined the expression level of JCV early proteins. We also investigated 
the basal expression level of a protein linked with large T antigen, p53, and 
Bag3. As shown in Figure 17 panel A, the expression level of both large T 
antigen and small t antigen proteins is lower in BSB8-RR cells compared to 
BSB8 cells. As expected, BS1A cells were negative for large T antigen. 
Furthermore, differences in the level of p53 and Bag3 were observed. In 
particular, BSB8 and BSB8-RR cells expressed higher level of p53 compared 
to BS1A cells, probably because of the presence of large T antigen. In fact, 
BSB8 cells level of p53 is higher compare to BSB8-RR cells. On the other 
hand, BS1A cells expressed higher level of Bag3 compare to BSB8 and 
BSB8-RR cells. Next, we performed a time point assay on BSB8 and BSB8-
RR cells to monitor the level of protein expression after radiation treatment. 
We irradiate the cells with 6-Gy dose of radiation and we did a whole cell 
extraction forty-eight and seventy-two hours post treatment. Changing in JCV 
early proteins levels was evaluated through western blot. As shown in Figure 
17 panel B, forty-eight hours after radiation, the level of large T antigen, as 
well as the level of small t antigen, in BSB8 irradiated cells was lower 
compared to the BSB8 control, while the level of large T antigen and small t 
antigen in BSB8-RR irradiated cells was similar to the BSB8-RR control. 
Interestingly, seventy-two hours after radiation, the level of large T antigen in 
BSB8-RR irradiated was higher than the BSB8-RR control, while the level in 
BSB8 irradiated was still lower than BSB8 control.  
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Figure 17. Large T antigen expression is suppressed in BSB8-RR cells. Panel A: 
Basal expression level of JCV early proteins in BS1A, BSB8 and BSB8-RR cells. 
Panel B: expression level of JCV early proteins in BSB8 and BSB8-RR cells after 
radiation treatment.  
 
4.1.4 BSB8-RR cells show increased cell-cycle and grow faster 
than BSB8 cells 
Since BSB8 are cells derived from medulloblastoma, we wanted to evaluate 
the growth characteristic and tumorigenesis capacity of BSB8 and BSB8-RR 
cells.  In order to investigate their cell cycle, we starved the cells for twenty-
four hours, culturing them in DMEM without FBS. We replaced FBS and we 
harvested cells at three time points, 0h-12h-24h, after replacing FBS. Cells 
were then fixed, incubated with propidium iodide and cell cycle analysis was 
performed using flow cytometry. Cell cycle analysis of BSB8 and BSB8-RR. 
is shown in panel A of Figure 18: at time point 0h and 12h BSB8 and BSB8-
RR cells are at the same cell cycle phase. Interestingly, at time point 24h, we 
observed that about 70% of BSB8-RR cells were in G1/G0 phase, and 15% 
were in G2/M phase. Regarding BSB8 cells, only about 50% were in G1/G0 
phase at time point 24h, while 30% of BSB8 cells were G2/M phase. BSB8 
cells maintained the same cell cycle among the three time points. Following 
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cell cycle analysis, we investigate the tumorigenesis capacity of these cells. 
We performed a colony formation assay and soft agar growth assay and, as 
seen in panels B and C of Figure 18, BSB8-RR cells are able to make more 
colonies in both assays, compared to BSB8 cells. The colony intensity of 
BSB8-RR cells is 4 times higher than BSB8 (panel B) and the number of 
colonies formed by BSB8-RR cells is two third than BSB8 (panel C). These 
results suggest that BSB8-RR cells proliferate faster than BSB8 cells and 
they have a more aggressive phenotype. 
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Figure 18. Growth characteristic of BSB8 and BSB8-RR. Panel A: Cell cycle analysis 
of BSB8 and BSB8-RR cells at three time point after FBS deprivation. Panel B: 
Colony formation assay after transfection with pcDNA3.1 and selection with G418. 
Panel C: Soft agar growth after transfection with pcDNA3.1 and selection with G418. 
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4.1.5 BSB8-RR cells show reduced NHEJ but increased HR 
activity than BSB8 cells 
Since ionizing radiation causes DNA breaks and JCV large T antigen is 
involved in some DNA repair pathways, we wanted to investigate if the 
different expression level of T antigen in BSB8 cells and BSB8-RR has a role 
in DNA repair. We performed two types of DNA repair assay to evaluate the 
efficiency in repairing DNA: non-homologous end joining (NHEJ) and 
homologous recombination (HR). For the NHEJ assay, we prepared a 
nuclear extract from BSB8 and BSB8-RR cells. Figure 19 shows that nuclear 
extracts from BSB8-RR cells, lane 4, have lower NHEJ activity than the 
nuclear extracts from BSB8 cells, lane 3. In fact, in both lane 3 and 4 we can 
see the monomeric linear plasmid DNA at 3000 bp but in lane 3 we can see 
more multimeric DNA concatamers.  
 
 
Figure 19. Non homologous end-joining (NHEJ) activity in nuclear extracts from 
BSB8 and BSB8-RR. Lane 2 is negative control without any nuclear extract. Lane 3 
is with nuclear extracts of BSB8 cells. Lane 4 is nuclear extracts of BSB8-RR cells. 
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For the HR assay, we first performed a transient assay, transfecting cells 
with both pDRGFP and pCBASceI plasmids and pDsRedl-Mito for 
transfection efficiency. We transfected the cells with two different amount of 
pDRGFP plasmid: 3 µg and 6 µg. Seventy-two hours after transfection, we 
harvested the cells and flow cytometry was used to calculate the percentage 
of green and red positive cells. We harvested the cells at one time point 
because, since the transfection is transient, if we wait more days, we will lose 
the plasmid expression. The efficiency in repairing DNA using homologous 
recombination was established as the percentage of cells positive for both 
green and red fluorescence normalized with cells positive only for red 
fluorescence. In panel A of Figure 20, representative scatter plots of 
untransfected cells, transfected BSB8 and BSB8-RR with pCBASceI and 
pDsRedl-Mito but not pDRGFP (these are the cells only red positive) and 
BSB8 and BSB8-RR transfected with all three plasmids (these are cells both 
positive for green and red fluorescence). In panel B of Figure 20, 
quantification of GFP positive cells, normalized to the transfection efficiency. 
Quantification shows a lower ability of BSB8 cells, compared to BSB8-RR 
cells, to repair DNA using homologous recombination.  
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Figure 20. Panel A: Representative scatter plots of untransfected cells, transfected 
BSB8 and BSB8-RR with pCBASceI and pDsRedl-Mito but not pDRGFP and BSB8 
and BSB8-RR transfected with pCBASceI + pDsRedl-Mito + pDRGFP. Panel B: 
Quantification of green positive cells. 
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Following transient transfection, we noticed the low percentage of green cells 
so we thought it would be better create stable cells for DRGFP. Once we 
grew stable cells for DRGFP, we transfected both BSB8-DRGFP and BSB8-
RR-DRGFP with pDsRedl-Mito only or with pCBASceI. We harvested the 
cells at five days post transfection and we performed flow cytometry analysis 
as done for transient transfection. In Figure 21, panel A, representative 
scatter plots of BSB8 and BSB8-RR DRGFP stable cells transfected with or 
without pCBASceI. In Figure 21, panel B, quantification of HR events shows 
that also in DRGFP stable cells, BSB8-RR cells have a better ability to repair 
DNA through homologous recombination. 
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Figure 21. Panel A: Representative scatter plots of transfected BSB8 and BSB8-RR 
with pDsRedl-Mito and BSB8 and BSB8-RR transfected with pCBASceI + pDsRedl-
Mito. Panel B: Quantification of green positive cells.  
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5. DISCUSSION 
5.1 Impact of large T antigen on resistance to radiation in JCV 
induced tumors  
JCV is a small, naked tumor polyomavirus with an icosahedral capsid 
containing a circular, double-stranded DNA genome. Its genome is divided 
into early and late genes, separated by a non-coding control region (NCCR) 
containing the promoter, the origin of replication (ORI) and the enhancer 
elements. Early genes encode for large T antigen, small t antigen and three 
different T’ proteins called T’135, T’136 and T’165. Late genes encode for 
the structural proteins VP1, VP2 and VP3, and the non-structural agnoprotein 
[49]. JCV shows specie-specificity to humans, probably due to the large T 
antigen can interact only with the human DNA polymerase. JCV has also 
tissue tropism for specific human cells, such as glial cells and kidney 
epithelial cells [34].  
One example of human cells infection is the lytic infection of 
oligodendrocytes, that are destroyed during the process, leading to the PML, 
the progressive multifocal leukoencephalopathy, a rare but fatal 
demyelinating pathology in the brain [35]. If the expression of early genes is 
followed by the replication of viral DNA and expression of late genes, we 
have a productive infection. If the infection occurs in non-permissive cells, 
they are not able to support viral replication or the expression of late genes. 
In those cells, only the expression of early genes, such as large T antigen, is 
observed. The expression of this viral protein leads to genome instability and 
inactivation of oncosuppressor proteins that eventually can lead to 
tumorigenesis [2]. 
In 1999, Krynska et al, induced brain tumors in transgenic mice injecting the 
JCV early region in mouse embryos [106]. This brain tumor was very similar 
to human medulloblastoma in location, histological appearance and 
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expression of markers for differentiation. Medulloblastoma is a malignant, 
very aggressive tumor of the cerebellum and it is one of the most common 
cancer in children. In 2000, Krynska et al, derived two distinct populations of 
cells from the JCV T antigen transgenic mice previously described [107]. 
These two populations showed a very different morphological features in 
cytoplasm and processes but, most important, they have different expression 
of JCV early proteins. One population is T antigen-negative (BS1A cells), the 
other one is T antigen-positive (BSB8 cells). 
Radiotherapy is part of cancer treatment in many patients with some form of 
cancer. In fact, radiotherapy is probably the most important treatment of 
localized tumors, after surgery. Since BS1A and BSB8 are tumor derived cell 
lines, we first examined whether ionizing radiation has an impact on their 
viability. We irradiated those cells with different doses of radiation and we 
performed an MTT viability assay. From our results, ionizing radiations had 
no impact on BS1A cells, but we had a reduction in BSB8 viability. The 
reduction is visible even at the lowest dose of radiations. BS1A are resistant 
to radiation because they are immortal but not transformed cells. In fact, after 
they populate, they have contact inhibition. They do not replicate and 
radiation is effective only on replicating cells. To complete the understanding 
of how radiations impact viability in BS1A and BSB8, we looked at the 
expression of proteins involved in apoptosis and autophagy. Our results 
show a stimulation of apoptosis by radiation in BSB8 but not in BS1A, in a 
dose dependent manner. The activation of Caspase-3 and its pathway in the 
cells is a signal of apoptosis [111]. Autophagy is stimulated in both BSB8 and 
BS1A cells, as we can see from the conversion of LC3-I to LC3-II. These 
results show a reduced viability in BSB8 after ionizing radiation because of 
apoptosis pathways have been activated. Surprisingly, the level of large T 
antigen in BSB8 after radiation is reduced, suggesting that it may have a role 
in the sensibility to ionizing radiation.  
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While performing the viability assay, we noticed that a very small sub-
population of BSB8 cells were still viable after radiations. We decided to try 
to culture these cells to see if they were able to repopulate. These cells were 
growing very fast and we decided to denominate them as BSB8-Radiation 
Resistant (BSB8-RR). In order to characterize this sub-population, we first 
confirmed that they were able to resist to a second radiation. We plated BSB8 
and the new BSB8-RR and we irradiated them with ionizing radiations. As 
expected, BSB8-RR viability did not change after radiations, while BSB8 
viability dropped because of cell death. We did confirm the resistance to 
radiation of BSB8-RR cells.  
After confirmed that BSB8-RR cells were resistant to radiations, we wanted 
to investigate if JCV early proteins may have a role in this resistance. First, 
we examined the basal expression level of the antigens in BS1A, BSB8 and 
BSB8-RR. As expected, no antigens level has been detected in BS1A. 
Interestingly, in BSB8-RR cells the levels of both large T antigen and small t 
antigen are lower compared to their levels in BSB8 cells. Furthermore, we 
saw differences in the level of p53, with a higher level of p53 in BSB8 and 
BSB8-RR compare to BS1A. This result was expected because p53 is being 
known to interact with large T antigen[112]. The binding between large T 
antigen and p53 results in uncontrolled cell spread. T antigen removes the 
ability of p53 to enhance transcription of p21/WAF-1, an inhibitor of cyclin 
kinases. In normal condition, a reduction in the kinase activity of G1/S 
cyclins:cdks keeps pRb in a hypophosphorylated state so it can sequester 
E2F. If E2F is no longer bound to pRb, it can promote unscheduled 
transcription of S phase genes [95]. To gain insight into the role of large T 
antigen and its expression level in response to irradiating radiation, we 
evaluated its expression level in a time-point treatment. We irradiated cells 
and we harvested them forty-eight and seventy-two hours after radiation. The 
fact that the level of large T antigen changes in response to radiation during 
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the time-point analysis suggested an implication of this protein in the 
resistance to radiation. The level in BSB8 cells decreases dramatically, as 
these cells are dying. The level in BSB8-RR changes between treatment, 
maybe because of a reactivation in their tumorigenic phenotype. 
The second step in the characterization of BSB8-RR cells was to analyze 
their cell-cycle after a starvation period and their tumorigenic capacity. BSB8 
and BSB8-RR are cells derived from medulloblastoma, known to be a very 
aggressive tumor. We were expecting a very aggressive phenotype but we 
wanted to see if the resistance to radiation had impacted this capacity. Large 
T antigen is the major player in cell transformation, its domains can bind and 
inactivate cellular proteins, that typically stop the entry into S phase, to force 
the cell cycle from G1 into S phase [2]. Since large T antigen levels are higher 
in BSB8 cells then BSB8-RR cells, we predicted more BSB8 cells in G2/M 
phases compare to BSB8-RR that we were expecting in G1/G0 phases. Our 
results on cell cycle after FBS starvation show that both cell lines share the 
same cell cycle phase in the first twelve hours, where they are synchronized 
after starvation. After twenty-four hours, there are more BSB8 cells in G2/M 
phase, confirming the ability of large T antigen to drive cells in S and then 
G2 phase. In contrast to this analysis, we observed a faster growth in cell 
culture flask of BSB8-RR than BSB8, suggesting a more tumorigenic 
phenotype. To validate this observation, we performed two assays to 
evaluate this tumorigenesis. The first assay was a colony formation assay, 
where we transfected cells with a plasmid carrying a gene for resistance to a 
specific antibiotic. Using this antibiotic in the culture medium we were able to 
select cells that were transfected and we let them form colonies. After three 
weeks we fixed, stained and counted the colonies. A higher number of 
colonies formed means a more tumorigenic phenotype. The second assay 
performed was similar to the colony formation assay but the culture media 
was supplemented with agar. This assay is a method for characterizing the 
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ability of transformed cells to grow independently of a solid surface, an ability 
called anchorage-independent growth [113]. This assay is considered to be 
one of the most stringent tests for malignant transformation in cells. Both 
cells are able to form colonies in soft agar, meaning that these cells show 
anchorage-independent growth ability. Normal cells are dependent on the 
contact between cells and extracellular matrix in order to grow and divide. 
Conversely, transformed cells are able to grow and divide independently of 
the environment where they are. If we count the number of colonies formed 
by BSB8 and BSB8-RR, it is very clear that BSB8-RR showed a more 
tumorigenic phenotype compared to BSB8.  
The last step in BSB8-RR characterization was to understand why these cells 
are resistant to radiation. As already said, radiations can cause DNA double 
strand breaks (DSBs), and cells that are not able to repair DNA damage 
usually follow a cell death fate. We then hypothesized that BSB8-RR may be 
resistant to radiation because they are able to repair better and/or faster the 
DNA DSBs caused by ionizing radiations. Two of the major pathways to 
repair DNA DSBs are: non-homologous end joining (NHEJ) and homologous 
recombination (HR). HR seems to be preferred in proliferating cells, while 
NHEJ seems to be preferred in quiescent cells [114]. NHEJ is "non-
homologous" because a homologous template is not necessary, the break is 
repaired with a direct ligation between the two ends. Homologous 
recombination needs a homologous sequence to perform the repair. 
Previous studies from our laboratory have shown an attenuation of 
homologous recombination in cells presenting large T antigen [101]. Indeed, 
another protein that large T antigen can bind is the insulin receptor substrate 
1 (IRS-1). This protein is involved in the mechanism of DNA repair, in fact 
the IGF-1R/IRS-1 signaling pathway supports homologous recombination 
because of a direct binding between Rad51 and hypo-phosphorylated IRS-
1. When IGF-1R is stimulated, IRS-1 becomes phosphorylated and, in this 
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phosphorylated status it cannot interact with Rad51. Rad51 can translocate 
into the nucleus and stimulate homologous recombination [101, 102]. Large 
T antigen has an inhibitory role in HR because it sustains IRS-1:Rad51 
complex in the nucleus at the DNA damage site, preventing HR. This leads 
to an impairment in homologous recombination but NHEJ is still functional 
[101]. To assess if the lower expression of large T antigen in BSB8-RR could 
lead to a major functionality in HR and so in repair DNA DSBs we performed 
DNA repair assays, NHEJ and HR. Our results show a functional NHEJ 
repair assay in both cells, but with a lower NHEJ activity in BSB8-RR 
compare to BSB8. This result was predictable, because BSB8 are more in a 
quiescent status and large T antigen has no impact on NHEJ functionality. 
On the other hand, HR is more efficient in BSB8-RR cells, in both transient 
transfection and stable cells line. We decided to create a stable cell line for 
DRGFP because HR assay needs time. In this assay we evaluated cell cycle 
related DNA repair assay, cells need time to grow and divide in order to 
perform HR. Transient transfection shows the same results as stable cell 
lines but the count of GFP positive cells per RED positive cells was very low 
in transient transfection. The presence of higher level of large T antigen in 
BSB8 cells may lead to an impairment in the repair of DSBs caused by 
ionizing radiations. Thus, when we irradiate BSB8 cells with ionizing 
radiations, their viability is compromised, they start dying because they can 
not repair the breaks in the DNA. Unlike BSB8, the lower level of large T 
antigen in BSB8-RR permits a more efficient, and error-free, repair of DSBs 
caused by ionizing radiations, allowing BSB8-RR cells to survive and 
proliferate. 
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6. CONCLUSION 
In this thesis we characterized a new type of BSB8 cells, denominated BSB8-
RR. These cells show a resistance to ionizing radiation, compared to the 
wild-type BSB8. We first demonstrated the effective resistance to a second 
radiation of BSB8-RR. We then investigated the level of large T antigen 
expression in these two cell lines and we characterized their growth 
characteristic and their tumorigenesis, anchorage-dependent or 
independent. After showing a more tumorigenic phenotype of BSB8-RR 
compared to the BSB8 cells, we investigated the ability of these cells in 
repairing DNA DSBs. BSB8 cells have an increase in NHEJ pathway while 
BSB8-RR perform a better HR repair. We hypothesized a direct effect of 
large T antigen in DNA repair, because it has been demonstrated that this 
protein inhibits HR. We confirmed that the difference in large T antigen level 
in BSB8 and BSB8-RR has consequences on homologous recombination 
efficacy. As a consequence of the lower level of large T antigen in BSB8-RR 
cells and better DNA repair, this protein may not even be necessary for their 
growth. Our future directions are to knock-down large T antigen in both BSB8 
and BSB8-RR cells using shRNA for large T antigen and CRISPR/Cas9 
system, previously developed in our department [115]. Our idea is that BSB8-
RR viability is now independent from large T antigen and, even without this 
protein, BSB8 are able to grow and divide. We will knock-down large T 
antigen and we will perform colony formation assay. Furthermore, we want 
to study the effect of splicing factors protein on T antigen expression. We 
created different plasmid, for transient and stable expression, of all the twelve 
splicing factors protein known so far. We would like to investigate if over-
expression of these splicing factors protein can influence large T antigen 
expression, as already described in our lab for SRSF1 [116-118]. 
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